Quantitative analysis of PiB-PET with FreeSurfer ROIs

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Su, Yi ^a   D'Angelo, Gina M ^a   Vlassenko, Andrei G ^a   Zhou, Gongfu ^a   Snyder, Abraham Z ^a   Marcus, Daniel S ^a   Blazey, Tyler M ^a   Christensen, Jon J ^a   Vora, Shivangi ^a   Morris, John C ^a   Mintun, Mark A ^b   Benzinger, Tammie L S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Avid Radiophamaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PROTEIN; CARBON N METHYL 2 (4 METHYLAMINOPHENYL)6 HYDROXYBENZOTHIAZOLE C11; TRACER; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOMATION; BRAIN REGION; COMPUTER ANALYSIS; COMPUTER PROGRAM; CONTROLLED STUDY; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGING SYSTEM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PROCESS DEVELOPMENT; QUANTITATIVE ANALYSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BENZOTHIAZOLES; BRAIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROIMAGING; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SOFTWARE;

EID: 84892402771     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073377     Document Type: Article

References (52)

1. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM (2007) Forecasting the global burden of Alzheimer's disease. Alzheimer's and Dementia 3: 186-191.
2. Nordberg A, Rinne JO, Kadir A, Langstrom B (2010) The use of PET in Alzheimer disease. Nat Rev Neurol 6: 78-87.
3. Morris JC, Price AL (2001) Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. JMolNeurosci 17: 101-118.
4. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, et al. (2010) APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 67: 122-131.
5. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356.
6. Holtzman DM, Morris JC, Goate AM (2011) Alzheimer's Disease: The Challenge of the Second Century. Science Translational Medicine 3: 77sr71-77sr71.
7. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, et al. (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55: 306-319.
8. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, et al. (2007) Imaging betaamyloid burden in aging and dementia. Neurology 68: 1718-1725.
9. Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, et al. (2007) PET amyloid ligand [11C] PIB uptake is increased in mild cognitive impairment. Neurology 68: 1603-1606.
10. Morris JC, Roe CM, Grant EA, Head D, Storandt M, et al. (2009) Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 66: 1469-1475.
11. Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, et al. (2006) [11C] PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67: 446-452.
12. Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, et al. (1990) Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(2)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 10: 740-747.
13. Roe CM, Mintun MA, D'Angelo G, Xiong C, Grant EA, et al. (2008) Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. Arch Neurol 65: 1467-1471.
14. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, et al. (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65: 1509-1517.
15. Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, et al. (2005) Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 25: 1528-1547.
16. Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, et al. (2005) Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 46: 1959-1972.
17. Lowe VJ, Kemp BJ, Jack CR Jr, Senjem M, Weigand S, et al. (2009) Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med 50: 878-886.
18. Raniga P, Bourgeat P, Fripp J, Acosta O, Villemagne VL, et al. (2008) Automated (11) C-PiB standardized uptake value ratio. Acad Radiol 15: 1376-1389.
19. Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, et al. (2009) Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 132: 1355-1365.
20. Edison P, Brooks DJ, Turkheimer FE, Archer HA, Hinz R (2009) Strategies for the generation of parametric images of [11C] PIB with plasma input functions considering discriminations and reproducibility. Neuroimage 48: 329-338.
21. Mikhno A, Devanand D, Pelton G, Cuasay K, Gunn R, et al. (2008) Voxel-based analysis of 11C-PIB scans for diagnosing Alzheimer's disease. J Nucl Med 49: 1262-1269.
22. Rosario BL, Weissfeld LA, Laymon CM, Mathis CA, Klunk WE, et al. (2011) Inter-rater reliability of manual and automated region-of-interest delineation for PiB PET. Neuroimage 55: 933-941.
23. Li Y, Rinne JO, Mosconi L, Pirraglia E, Rusinek H, et al. (2008) Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur J Nucl Med Mol Imaging 35: 2169-2181.
24. Reiman EM, Chen K, Liu X, Bandy D, Yu M, et al. (2009) Fibrillar amyloidbeta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 106: 6820-6825.
25. Grimmer T, Tholen S, Yousefi BH, Alexopoulos P, Forschler A, et al. (2010) Progression of cerebral amyloid load is associated with the apolipoprotein E epsilon4 genotype in Alzheimer's disease. Biol Psychiatry 68: 879-884.
26. Fischl B, Salat DH, Busa E, Albert M, Dieterich M, et al. (2002) Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 33: 341-355.
27. Desikan RS, Segonne F, Fischl B, Quinn BT, Dickerson BC, et al. (2006) An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 31: 968-980.
28. Fischl B, van der Kouwe A, Destrieux C, Halgren E, Segonne F, et al. (2004) Automatically parcellating the human cerebral cortex. Cereb Cortex 14: 11-22.
29. Mueller SG, Schuff N, Yaffe K, Madison C, Miller B, et al. (2010) Hippocampal atrophy patterns in mild cognitive impairment and Alzheimer's disease. Hum Brain Mapp 31: 1339-1347.
30. Lehmann M, Rohrer JD, Clarkson MJ, Ridgway GR, Scahill RI, et al. (2010) Reduced cortical thickness in the posterior cingulate gyrus is characteristic of both typical and atypical Alzheimer's disease. J Alzheimers Dis 20: 587-598.
31. Messina D, Cerasa A, Condino F, Arabia G, Novellino F, et al. (2011) Patterns of brain atrophy in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy. Parkinsonism Relat Disord 17: 172-176.
32. Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, et al. (2012) Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 72: 578-586.
33. Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, et al. (2009) Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 132: 1310-1323.
34. Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, et al. (2013) Amyloid-beta Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods. J Nucl Med 54: 70-77.
35. Morris JC (1993) The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43: 2412-2414.
36. Berg L (1988) Clinical Dementia Rating (CDR). PsychopharmacolBull 24: 637-639.
37. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, et al. (2003) Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. JMedChem 46: 2740-2754.
38. Robb RA, Hanson DP, Karwoski RA, Larson AG, Workman EL, et al. (1989) Analyze: a comprehensive, operator-interactive software package for multidimensional medical image display and analysis. Comput Med Imaging Graph 13: 433-454.
39. Eisenstein SA, Koller JM, Piccirillo M, Kim A, Antenor-Dorsey JA, et al. (2012) Characterization of extrastriatal D2 in vivo specific binding of [(18) F] (N-methyl) benperidol using PET. Synapse.
40. Rowland DJ, Garbow JR, Laforest R, Snyder AZ (2005) Registration of [18F] FDG microPET and small-animal MRI. Nucl Med Biol 32: 567-572.
41. Hajnal JV, Saeed N, Soar EJ, Oatridge A, Young IR, et al. (1995) A registration and interpolation procedure for subvoxel matching of serially acquired MR images. J Comput Assist Tomogr 19: 289-296.
42. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, et al. (1996) Distribution volume ratios without blood sampling from graphical analysis of PET data. JCerebBlood Flow Metab 16: 834-840.
43. Meltzer CC, Zubieta JK, Brandt J, Tune LE, Mayberg HS, et al. (1996) Regional hypometabolism in Alzheimer's disease as measured by positron emission tomography after correction for effects of partial volume averaging. Neurology 47: 454-461.
44. Sheline YI, Price JL, Yan Z, Mintun MA (2010) Resting-state functional MRI in depression unmasks increased connectivity between networks via the dorsal nexus. Proc Natl Acad Sci U S A 107: 11020-11025.
45. Galvin JE, Fagan AM, Holtzman DM, Mintun MA, Morris JC (2010) Relationship of dementia screening tests with biomarkers of Alzheimer's disease. Brain 133: 3290-3300.
46. Marcus DS, Olsen TR, Ramaratnam M, Buckner RL (2007) The Extensible Neuroimaging Archive Toolkit: an informatics platform for managing, exploring, and sharing neuroimaging data. Neuroinformatics 5: 11-34.
47. Illarioshkin SN, Vlassenko AG, Fedotava EY (2013) Current means for identifying the latent stage of a neurodegenerative process. Annals of Clinical and Experimental Neurology (Moscow) 7: 39-50.
48. Jack CR Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, et al. (2008) 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 131: 665-680.
49. Haxby JV, Gobbini MI, Furey ML, Ishai A, Schouten JL, et al. (2001) Distributed and overlapping representations of faces and objects in ventral temporal cortex. Science 293: 2425-2430.
50. Meltzer CC, Kinahan PE, Greer PJ, Nichols TE, Comtat C, et al. (1999) Comparative evaluation of MR-based partial-volume correction schemes for PET. J Nucl Med 40: 2053-2065.
51. Jovicich J, Czanner S, Han X, Salat D, van der Kouwe A, et al. (2009) MRI-derived measurements of human subcortical, ventricular and intracranial brain volumes: Reliability effects of scan sessions, acquisition sequences, data analyses, scanner upgrade, scanner vendors and field strengths. Neuroimage 46: 177-192.
52. Klein A, Andersson J, Ardekani BA, Ashburner J, Avants B, et al. (2009) Evaluation of 14 nonlinear deformation algorithms applied to human brain MRI registration. Neuroimage 46: 786-802.